SCHEMBL30965845

SCHEMBL30965845

Nc1ncnc2c1ncn2[C@@H]1O[C@H](C[S+](CC[C@H](N)C(=O)O)CC(=O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 5/20 0.78
AMD1 P17707 2/20 0.78
NNMT P40261 4/20 0.70
DOT1L Q8TEK3 5/20 0.69
EHMT2 Q96KQ7 4/20 0.69
PCMT1 P22061 3/20 0.69
NSD2 O96028 3/20 0.69
SETD7 Q8WTS6 3/20 0.69
PRMT5 O14744 3/20 0.69
PRMT1 Q99873 3/20 0.69
NSD3 Q9BZ95 2/20 0.69
TRDMT1 O14717 2/20 0.69
INMT O95050 2/20 0.69
METTL3 Q86U44 2/20 0.69
EHMT1 Q9H9B1 2/20 0.69
METTL14 Q9HCE5 2/20 0.69
RNMT O43148 1/20 0.69
TPMT P51580 1/20 0.69
NSD1 Q96L73 1/20 0.69
SETD2 Q9BYW2 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30388331 0.94 CARM1 (0.77) CARM1AMD1NNMTDOT1LEHMT2
SCHEMBL2287096 0.91 CARM1 (0.81) CARM1AMD1NNMTDOT1LEHMT2
SCHEMBL2287090 0.91 CARM1 (0.81) CARM1AMD1NNMTDOT1LEHMT2
SCHEMBL30930805 0.91 CARM1 (0.78) CARM1AMD1NNMTDOT1LEHMT2
SCHEMBL2287080 0.91 CARM1 (0.81) CARM1AMD1NNMTDOT1LEHMT2
SCHEMBL2284764 0.90 CARM1 (0.79) CARM1AMD1NNMTDOT1LEHMT2
SCHEMBL2284758 0.90 CARM1 (0.79) CARM1AMD1NNMTDOT1LEHMT2
SCHEMBL2284776 0.90 CARM1 (0.79) CARM1AMD1NNMTDOT1LEHMT2
SCHEMBL2288248 0.89 CARM1 (0.74) CARM1AMD1NNMTDOT1LEHMT2
SCHEMBL2293226 0.89 CARM1 (0.74) CARM1AMD1NNMTDOT1LEHMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070361-A Method for amplifying methylated DNA 辛戴克斯生物有限公司 2026-05-19 CN disclosed
US-20260015677-A1 METHYLATION METHOD SYNDEX BIO LTD (GB) 2026-01-15 US disclosed
US-20250283170-A1 MODIFIED ADAPTERS FOR ENZYMATIC DNA DEAMINATION AND METHODS OF USE THEREOF FOR EPIGENETIC SEQUENCING OF FREE AND IMMOBILIZED DNA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2025-09-11 US disclosed
WO-2025032340-A1 METHOD OF AMPLIFYING METHYLATED DNA SYNDEX BIO LTD (GB) 2025-02-13 WO disclosed
EP-4370711-A1 MODIFIED ADAPTERS FOR ENZYMATIC DNA DEAMINATION AND METHODS OF USE THEREOF FOR EPIGENETIC SEQUENCING OF FREE AND IMMOBILIZED DNA The Trustees of the University of Pennsylvania (US) 2024-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015677-A1 METHYLATION METHOD DNMT3A, DNMT1, DNMT3L CARM1 616/4885AMD1 79/4885NNMT 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.